[Results of postoperative treatment of glioblastoma multiforme with a radiation-sensitizing substance (5-bromo-2-deoxyuridine)].
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000209:etiology; D001929:Brain Edema / Q000209:etiology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D001973:Bromodeoxyuridine / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D005076:Exanthema / Q000209:etiology; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D005928:Glossitis / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011182:Postoperative Care; D011379:Prognosis; D011838:Radiation-Sensitizing Agents; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
D011838:Radiation-Sensitizing Agents; D001973:Bromodeoxyuridine; D008727:Methotrexate
Resultate der postoperativen Behandlung des Glioblastoma multiforme mit einer strahlensensibilisierenden Substanz (5-Bromo-2'-deoxyuridin.